
Verve Therapeutics (VERV) Stock Forecast & Price Target
Verve Therapeutics (VERV) Analyst Ratings
Bulls say
Verve Therapeutics is viewed positively due to its innovative approach to transforming the treatment of cardiovascular disease through single-course gene editing medicines, addressing critical weaknesses in the current chronic care model. The company has a solid financial position, boasting $540 million in cash, providing a runway through mid-2027 which supports its ongoing research and development efforts. Additionally, the recent licensing agreement with BEAM for base editing technology, coupled with an industry-high $300 million upfront payment and potential $1.05 billion in milestones, demonstrates significant pharmaceutical interest and validates Verve's strategic direction in the gene-editing market.
Bears say
Verve Therapeutics Inc. reported a significant net loss of $50 million for 4Q24, translating to a loss of $0.58 per share, with projections indicating a full-year 2025 net loss of $2.38 per share, underscoring the company's non-revenue generating status. The company's pipeline remains in early stages without near-term catalysts, heightening concerns about the unpredictability of future revenues and expenses amidst high regulatory hurdles and market risks. Additionally, potential delays in clinical assessments and unfavorable data from ongoing programs, combined with the possibility of long-term dilution risks, further exacerbate the negative outlook for the company's stock.
This aggregate rating is based on analysts' research of Verve Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Verve Therapeutics (VERV) Analyst Forecast & Price Prediction
Start investing in Verve Therapeutics (VERV)
Order type
Buy in
Order amount
Est. shares
0 shares